The report "Point of Care/ Rapid Diagnostics Market by Product (Glucose, HIV, Hepatitis C, Pregnancy), Platform (Microfluidics, Dipstick, Immunoassay), Purchase (OTC, Prescription), Sample(Blood, Urine), User (Pharmacy, Hospital, Homecare) - Global Forecast to 2027", is expected to reach USD 75.5 billion by 2027 from an estimated USD 45.4 billion in 2022, at a CAGR of 10.7% from 2022 to 2027. Browse in-depth TOC on "Point of Care/ Rapid Diagnostics Market" 334 - Tables 48 - Figures 398 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=106829185 Factors such as increasing incidence of infectious diseases, rising number of CLIA-waived POC tests and supportive government policies, healthcare decentralization and greater investments and funding for new point-of-care testing product development are anticipated to drive the growth of the point-of-care and rapid diagnostics market during the forecast period. However, rising pricing pressure due to the budget constraints, and reimbursement cuts and are expected to hamper the growth of the point-of-care and rapid diagnostics market. “The Asia Pacific market is expected to grow at the highest CAGR during the forecast period” The global point-of-care and rapid diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe. The Asia Pacific market is projected to register the highest growth during the forecast period. Owing to the rising prevalence of cardiac diseases, diabetes, and infectious diseases, growing economy, expansion of healthcare infrastructure, growing initiatives by government boost the adoption of POCT, emergence of new rapid diagnostic kits manufacturer, and increased focus of key players to boost their distribution channel in the region. The major players operating in the point-of-care and rapid diagnostics market are Abbott (US), Becton, Dickinson and Company (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), and F. Hoffman-La Roche Ltd. (Switzerland), Quidel Corporation (US), Chembio Diagnostics (US), EKF Diagnostics (UK), Trinity Biotech plc (Ireland), Instrumentation Laboratory (a Werfen Company) (US), Nova Biomedical (US), PTS Diagnostics (US), Sekisui Diagnostics (US), Thermo Fisher Scientific (US), and bioMérieux SA (France). Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=106829185
Topics
